BACKGROUND: The safety and efficacy of nevirapine (NVP) and efavirenz (EFV) based highly active antiretroviral treatment (ART) with concurrent anti-tuberculosis treatment in sub-Saharan Africa has not been well established. METHODS: We performed a retrospective study comparing human immunodeficiency virus (HIV) infected adults exposed and not exposed to tuberculosis (TB) treatment with similar baseline HIV-1 RNA levels who were started on ART as part of Botswana's ART Programme. ART regimens, HIV-1 RNA, CD4+ cell count, and liver function tests were reviewed for 12 months following ART initiation. RESULTS: Among 155 patients on ART only and 155 exposed to TB treatment, there was no difference in virologic or immunologic response throughout the first year of ART. Furthermore, there remained no differences in virologic or immunologic outcomes when NVP and EFV groups were stratified by TB treatment exposure status. While more hepatotoxic events occurred in the group exposed to TB treatment than in those not exposed (9% vs. 3%, P = 0.05), there was no difference between patients treated with NVP and those treated with EFV. CONCLUSIONS: Patients co-infected with HIV and TB in Botswana can be treated effectively with either NVP- or EFV-based ART and TB treatment. As hepatotoxic events were more common in the group exposed to TB treatment, liver function tests should be monitored closely.
BACKGROUND: The safety and efficacy of nevirapine (NVP) and efavirenz (EFV) based highly active antiretroviral treatment (ART) with concurrent anti-tuberculosis treatment in sub-Saharan Africa has not been well established. METHODS: We performed a retrospective study comparing humanimmunodeficiency virus (HIV) infected adults exposed and not exposed to tuberculosis (TB) treatment with similar baseline HIV-1 RNA levels who were started on ART as part of Botswana's ART Programme. ART regimens, HIV-1 RNA, CD4+ cell count, and liver function tests were reviewed for 12 months following ART initiation. RESULTS: Among 155 patients on ART only and 155 exposed to TB treatment, there was no difference in virologic or immunologic response throughout the first year of ART. Furthermore, there remained no differences in virologic or immunologic outcomes when NVP and EFV groups were stratified by TB treatment exposure status. While more hepatotoxic events occurred in the group exposed to TB treatment than in those not exposed (9% vs. 3%, P = 0.05), there was no difference between patients treated with NVP and those treated with EFV. CONCLUSIONS:Patients co-infected with HIV and TB in Botswana can be treated effectively with either NVP- or EFV-based ART and TB treatment. As hepatotoxic events were more common in the group exposed to TB treatment, liver function tests should be monitored closely.
Authors: Shahin Lockman; Roger L Shapiro; Laura M Smeaton; Carolyn Wester; Ibou Thior; Lisa Stevens; Fatima Chand; Joseph Makhema; Claire Moffat; Aida Asmelash; Patrick Ndase; Peter Arimi; Erik van Widenfelt; Loeto Mazhani; Vladimir Novitsky; Stephen Lagakos; Max Essex Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Christopher J Hoffmann; Salome Charalambous; Chloe L Thio; Desmond J Martin; Lindiwe Pemba; Katherine L Fielding; Gavin J Churchyard; Richard E Chaisson; Alison D Grant Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: C Padmapriyadarsini; P K Bhavani; Alice Tang; Hemanth Kumar; C Ponnuraja; G Narendran; Elizabeth Hannah; C Ramesh; C Chandrasekar; Christine Wanke; Soumya Swaminathan Journal: Int J Infect Dis Date: 2013-09-13 Impact factor: 3.623
Authors: Nira R Pollock; Jason P Rolland; Shailendra Kumar; Patrick D Beattie; Sidhartha Jain; Farzad Noubary; Vicki L Wong; Rebecca A Pohlmann; Una S Ryan; George M Whitesides Journal: Sci Transl Med Date: 2012-09-19 Impact factor: 17.956
Authors: Natalie T Do; Kelesitse Phiri; Hermann Bussmann; Tendani Gaolathe; Richard G Marlink; C William Wester Journal: AIDS Res Hum Retroviruses Date: 2010-06 Impact factor: 2.205